



Innovations in Drug Resistance: A Commemorative Issue in Honor of Prof. Salvador Luria

Guest Editors:

Dr. Maria A. Bonifacio

Department of Precision and
Regenerative Medicine and
Ionian Area, University of Bari
Aldo Moro Medical School, 70124
Bari, Italy

Prof. Dr. Antonio Mazzocca

Interdisciplinary Department of
Medicine, University of Bari
School of Medicine, I-70124 Bari,
Italy

Prof. Dr. Anna Volpe

Clinic of Infectious Diseases,
Department of Biomedical
Sciences and Human Oncology,
University of Bari Aldo Moro, Bari,
Italy

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

Salvador Luria studied the development of bacterial resistance to phages, clarifying that mutations arise randomly and are selected by the presence of phages. The development of the Luria–Delbrück fluctuation test represents a brilliant moment in science, which opened up new landscapes in molecular genetics and led to Luria, Delbrück, and Hershey being awarded a Nobel Prize for their work. Indeed, it has been more than half a century since their study, but it is still relevant today, and Luria's pioneering work has provided elegant theoretical tools to face the drug resistance phenomenon, which continues to be a contemporary and challenging issue in microbiology and oncohematology.

All manuscripts providing answers to the above questions are welcome in this Special Issue, which is aimed at celebrating the work of Salvador Luria, on what would have been the year of his 110th birthday. Original research articles describing innovative studies approaches to deal with drug resistance will be considered for publication. Systematic reviews and critical analyses reporting the most promising strategies to overcome the rise of drug-resistant agents will be welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)